Trevi Therapeutics, Inc. (TRVI) Earnings Call Transcript & Summary

March 17, 2022

NASDAQ US Health Care Pharmaceuticals earnings 22 min

Earnings Call Speaker Segments

Jennifer Good

executive
#1

Hello, everyone, and thank you for being here on this call covering our business update along with results for Q4 and the full year of 2021. Joining me today are Trevi's Chief Financial Officer, Lisa Delfini, as well as Dr. Bill Forbes, who serves as our Chief Development Officer. Lisa and I have some prepared comments to share, and once we're done, the three of us will stick around to answer your questions. It's been an exciting stretch of months here at Trevi, and I'm happy to discuss the progress we've made in advancing both of our programs. As you may have seen, we shared recently that an interim analysis of our Phase 2 CANAL trial, which focuses on chronic cough and IPF, showed a reduction in cough that was statistically significant — a finding that allowed us to stop the study ahead of schedule. The outcome got a lot of notice from outside, and it allows us to accelerate what we had planned. Also, enrollment wrapped up on January 31, 2022, in the Phase 2b/3 PRISM study for chronic pruritus and PN. For our lead programs, these are important clinical development milestones, and they free us up to focus on preparing for the subsequent phases of development. The program furthest along in clinical development is aimed at severe chronic pruritus and prurigo nodularis, or PN — a serious, debilitating condition characterized by papules and nodules on the skin, plus unrelenting, severe itching. In our PRISM trial, a 14-week phase 2b/3 trial, Haduvio is being studied for PN. Top line results should come out during Q2 of this year. Given how stubborn this condition is, our view is that PN has a neurological basis and could align closely with how our mixed agonist antagonist drug works through neuronal pathways. Since nothing has been approved for this indication, we remain the furthest along oral treatment in development. Now for an update on the open label extension portion of our PN work. The percentage of participants who go on into the open label extension remains elevated, sitting at about 93%; from this we'll gain not only safety information over the long term, but also useful efficacy findings on skin healing and quality of life among these participants. Our thinking is that if you can bring itch down, a therapy that works could interrupt the cycle of scratching, and that should let the skin heal and generate changes in the disease over time. We view this as a sizable market opportunity, and our estimate for PN prevalence worldwide is roughly 730,000 patients — 300,000 of them in the U.S., with 430,000 across the rest of the world. The majority of these individuals have already gone through topical treatments without success, and our view is that they would qualify for an oral option such as Haduvio prior to moving on to biologics. Turning now to the second clinical program we have, covering chronic cough and idiopathic pulmonary fibrosis, or IPF: the past two weeks have been quite exciting where this program is concerned. We were glad to share that a pre-specified interim analysis produced a positive outcome, which let us stop enrollment sooner, cut costs, and move faster into the next stage of development. In that interim look, Haduvio showed a 77% reduction from baseline on day 22 in daytime cough frequency, as measured by an objective cough monitor — equivalent to a 52% difference compared with placebo. For this analysis, which involved 26 subjects, the p value was less than 0.0001, and conditional power hit 100%; results remained consistent regardless of baseline cough frequency or antifibrotic use, and we saw no impact from the treatment period in this crossover design. When we looked at patient-reported outcomes, they mirrored what the objective cost monitor showed — a quick reaction to treatment that started at week one. Haduvio is the top therapy in development and the only one that has shown favorable findings for lowering costs in this group of patients. Throughout the trial, Haduvio was well tolerated, with only a single FAE deemed not related to treatment, and the side effects were consistent with those seen in Haduvio studies and other indications. This week we announced that the last participant has been randomized in the trial, and we expect about 40 subjects overall to be assessed. Because the reported p value is so compelling, we expect the final dataset to show comparable results, and we plan to share topline findings for the entire subject population sometime in Q3 of this year. Our goal is to unveil the full results at a medical conference in the autumn. At the same time, Bill and his colleagues are laying the groundwork for the upcoming clinical trial — which we intend to structure as an adequate and well controlled study — while also getting ready for talks with regulators; these data are thrilling and offer early confirmation of what we hypothesized about how studio works to treat cough. Our team is figuring out how to move ahead, and that applies not only to this particular indication but to additional chronic cough uses as well. When we talk about chronic cough plus IPF, that sits inside a far bigger chance for chronic cough overall — spanning other interstitial lung diseases and the growing opening in refractory chronic cough. Around $10 billion is the estimated size of this worldwide chronic cough market. For some context on IPF: it's a severe, progressive illness in which lung tissue becomes scarred. Chronic coughing ranks among the most debilitating symptoms of this disease, showing up in as many as 85% of these patients, and there are no approved treatments for it. Within the U.S. Our estimate puts the IPF patient population at roughly 130,000, with a comparable figure for Europe. Given how high the five-year mortality rate is for IPF, both those who prescribe and those living with the condition want more than just slowing disease progression — they also want the patient's quality of life to get better. The past several months have been full of activity across both of our studies, yet we still have a stretch of months ahead that will bring plenty of data. In Q2, we will complete the double-blind portion of the pruritus study together with PN, and top-line results will be reported. We're also set to wrap up dosing and enroll the rest of the participants in our cost study and IPF, with data on the complete group of subjects expected to be reported in Q3. At the same time, we're busy getting ready for the next phase of development in both of those indications, and we're making plans for expanding into additional indications in chronic pruritus and chronic cough. Before handing things over to Lisa for the financial review, one last thing: on Wednesday, March 30, from 8 to 9 a.m. Eastern time, we'll hold a Kol call, where Bill will go over the interim results and share some additional new analyses. And what's really important is that Dr. We're going to have Lisa Lancaster with us—her role is professor of medicine at Vanderbilt University School in the School of Medicine. In addition, Dr. Lancaster is Medical Director for the Interstitial Lung Disease Program at Vanderbilt University Medical Center, and she acts as a medical advisor to the Pulmonary Rehabilitation Program at Vanderbilt. Her background includes extensive work with people who have interstitial lung disease, idiopathic pulmonary fibrosis among them, and she will be extremely valuable in shedding light on this condition and the experiences of those living with it; we're hoping you'll be on that call too. A press release containing registration instructions is going to be issued by us sometime in the coming week; that's all I had for the business update. Now I'll turn it over to Lisa to go through our financial results, and after that we'll take questions.

Lisa Delfini

executive
#2

Thanks, Jennifer, and hello everyone this afternoon. I should give you my usual reminder that you can find the complete financial results covering both the 3 and 12 months that closed on December 31 2021 in the press release we put out before this call, along with our 10-K, which was submitted to the SEC only a few minutes back. In Q4, we brought in $14.8 million through financing, and that let us finish the year holding a cash balance of $36.8 million. As Jennifer pointed out, we managed to stop enrollment in our CANAL trial sooner than planned, and the money we saved from that will assist us in moving faster on preparations for the next clinical trial targeting chronic cough and IPF. Our net loss for the fourth quarter of 2021 came to $8.5 million, whereas the comparable quarter of 2020 saw a net loss of $9.5 million. R&D expenses totaled $6.2 million in Q4 2021, versus $6.6 million during the same stretch of 2020 — mainly because we bought fewer clinical trial supplies, though that was partly offset by more activity in our CANAL trial and higher personnel-related expenses stemming from a larger headcount. G&A expenses came in at $2.1 million for the fourth quarter of 2021, compared with $2.6 million in the matching period of 2020, largely driven by lower market research costs. That wraps up our prepared remarks, and I'll hand the call back to the operator now for Q&A.

Annabel Samimy

analyst
#3

Hello, and thank you for taking my question. I actually have two. The first one concerns the CANAL program. What I'd like to understand is how you see the development pathway unfolding from here. The reason I'm asking is that several other chronic cough trials are underway in the P2X3 area, and while I realize this isn't directly tied to IPF, I'm wondering whether you think there's productivity or applicability for your program there. Could those P2X3 inhibitors have the same wide applicability for expanding into IPF? Basically, I want to hear how you expect the landscape to shake out. Thanks.

Jennifer Good

executive
#4

Thank you, Annabelle. I'll take that one, and I'll invite Bill to chime in if he has anything to add. Sure, so our long-held view has been that this mechanism has the potential to act broadly against cough. As the two of us have talked about, opioids have long been recognized as effective against cough. When it comes to IPF cough, I believe it's regarded as an especially severe and serious type of cough. In fact, a few of the P2X3 agents, including gefapixant, were tested in IPF cough and did in fact fail there. So the fact that we do work in that setting strikes us as a favorable signal. As we go forward, we're looking at refractory chronic cough along with cough from other interstitial lung diseases. Once all of our trial data have read out, I suspect we'll take a step back and consider the optimal approach to building out the company. Still, my feeling is that this mechanism could have broad applicability for cough.

Annabel Samimy

analyst
#5

All right, apologies — please continue.

Jennifer Good

executive
#6

We'll see whether he has anything he'd like to put in addition to what I said.

William Forbes

executive
#7

Not exactly on that point, but more around how we get to CANAL and what comes after — I believe that's where he began, Annabel. Something we clearly want to do is finish this trial and share the top-line results. In parallel, we'll be advancing the regulatory side, and we're beginning talks with ILD centers across the United States. So our expectation is that the following study will run in the UK as well as the US; and, as you can imagine, we're eager to engage the FDA and discuss with them what comes next and what's required of us. My expectation is that our meeting with the FDA happens during Q3, and after that we'll aim to have everything underway shortly afterward.

Annabel Samimy

analyst
#8

All right, and I suppose what prompted my question is that you're holding $36.8 in cash, and these markets are fairly substantial and could end up requiring a great deal of money to develop. So I'm trying to figure out how you'd finance this program as you move ahead, particularly given that certain key fact studies have demonstrated some failure in IPF, while others have demonstrated success in chronic cough and maybe possess a superior profile compared with those that didn't succeed. So I'm somewhat curious about how much she may need to put into this to dish in my soap.

Jennifer Good

executive
#9

Yes, so Annabel, you're correct. I mean, there are many indications here, which could become quite costly, I should simply note that IPF costs and PN are going to be our priority in the data, assuming both turn out successful; those each represent serious unmet patient needs and we're dedicated to sort of completing what we begin, and regarding where we go next, part of what we'll consider is what the programs cost, the pricing overall, the unmet need, all of those sorts of things; and we'll need to approach that mindfully. I mean, we're certainly mindful of where our stocks sit in the market capital. I believe there's a chance to do that. It's something we'll look at again. I know, Lisa, you might want to say something regarding cash runway planning?

Lisa Delfini

executive
#10

Right. So the money we have on hand carries us through the point where data comes out from both clinical trials, and then up to when we'd begin getting ready for the trial that follows. And we will — we recognize that raising funds for that next clinical trial is necessary. We'll be looking into it. We're aware that these cost results have brought added value to the company, and we'll be taking that into account as we work our way through the results at the end of the year.

Annabel Samimy

analyst
#11

All right, and then very briefly regarding the side effect profile — I realize that based on, I suppose, how it works, there was that nausea and vomiting you'd first attempted to tackle by titrating patients so they reach the proper dose. Did you observe that patients enrolled in the CANAL study struggled just as much during that titration phase with nausea and vomiting, and might that make things worse for this group, since their illness already leaves them somewhat susceptible when it comes to nausea and vomiting? I'm simply wondering how you reconcile those early-stage side effects against the condition itself?

William Forbes

executive
#12

Yes, a few quick remarks. Clearly, this patient population coughs an enormous amount, so vomiting truly is a problem for these patients. You can picture that if they're coughing as often as 90 times each hour, some of that could set in. Still, we've disclosed that, looking in a blinded manner, 5 AEs led to withdrawal from this trial. We have no idea which treatment arm those patients belonged to at the time they withdrew, though one was anorexia, one was depression, one was nausea, vomiting, one was insomnia, fatigue, and one was agitation, anxiety dyspnea. On the whole, I'd say we've felt quite good about the tolerability observed in this trial. We titrated the dose upward just as we do in the PRISM study. So, as I mentioned, on the whole we're pleased with what we're seeing. Beyond that, concerning the anti-fibrotic, plenty of GI side effects come along with anti-fibrotic treatment too; and we're aware that a bit under 50% of the population in this trial was receiving an anti-fibrotic. Given that, we recognize there's already a side effect profile stemming from one of the leading therapies in this space.

Jennifer Good

executive
#13

Thanks.

Annabel Samimy

analyst
#14

Thanks.

Analyst

analyst
#15

Hello, good afternoon. I have a few questions. The first is a follow-up to the question that just came before. In the CANAL trial, did the dose and titration protocol match what you're using in the PRISM study?

William Forbes

executive
#16

In the CANAL study, it was changed somewhat. In the CANAL study, we went from 27 mg to 54 milligrams, then kept escalating the dose to 108 and after that to 162. Obviously, we finished at that same dosage of 162 b.i.d.

Jennifer Good

executive
#17

And Bill, perhaps you could explain the reason behind that — you were looking to obtain some dose data, correct? It truly had nothing to do with tolerability.

William Forbes

executive
#18

Yeah, no, that's a key thing to bring up. When they first put this study together, we had <<inaudible>> recordings taken at baseline, then at week one, two, and three. So at the time the study was being designed, we were attempting to capture some dose response at each of those points, aiming to reach the 54, the 108, and then the 162 on the VitalChek <<inaudible>> recording. That's the reason it ended up being changed somewhat. Sadly, we were forced to eliminate the VitalChek <<inaudible>> recordings at weeks one and two as a result of COVID, and the in-patient visits we had hoped for weren't possible, but we did keep the VitalChek <<inaudible>> the baseline in week three; so I hope that addressed your question, Serge.

Analyst

analyst
#19

Yes. Then, turning to when the PRISM trial data will be released, since we're now just a handful of weeks into Q2, I believe you previously mentioned roughly a 4-month gap separating the final patient being enrolled and a possible readout — is that the correct frame of reference?

William Forbes

executive
#20

Yes, I'd say you ought to expect our readout to arrive at the close of Q2.

Analyst

analyst
#21

Understood, all right, thanks.

Nathan Weinstein

analyst
#22

I believe that's right. Good afternoon, Jennifer, Lisa, and Bill. I appreciate you taking my questions, and congratulations on the advances, especially the impressive interim analysis from CANAL. My first question is about Haduvio for patients with severe pruritus and TN — I believe during the prepared remarks you noted the possibility of using it in the protocol ahead of biologics. Could you elaborate on what that could mean, whether in terms of comparing or contrasting with that class, or what the implications might be for capturing share?

Jennifer Good

executive
#23

Yes, that's a good question. Biologics clearly matter; however, they aren't appropriate for everyone. From a payer standpoint, depending on where we decide to set the product's price, there may be a chance for it to become step-through therapy. I also think oral options tend to be simpler for patients and are generally the preferred approach; so we're considering that actively — how it benefits the patient, and from a payer standpoint it's likely less costly than the biologics.

Nathan Weinstein

analyst
#24

All right, that's reasonable. Maybe I'll just ask one more thing. You clearly said IPF cough and PN are where the attention is, but your pipeline is fairly deep, and there could be some appealing indications beyond the lead. What options exist — could a partnership be part of the strategy, or could you describe what you'd potentially go after strategically there?

Jennifer Good

executive
#25

Sure. We've actually had partnering talks going on, essentially preparing people for the data across recent years. I'd describe our partnering emphasis as centered on geographic territory. That means Asia, Japan and China plus similar territories, and Europe as well. We're a small U.S. based company. I believe we can perform well here, and I think we're comfortable developing in Europe, though definitely securing a partner in Asia to help advance the dragon, along with a marketing partner in Europe, are things that would benefit both the company and the asset. That's where our discussions are concentrated.

Nathan Weinstein

analyst
#26

All right, thanks, that's great. I really appreciate the detailed responses. I'm excited to see how things develop over the remainder of the year.

Jennifer Good

executive
#27

Thanks, Nathan.

Jennifer Good

executive
#28

We appreciate everyone joining us on today's call. Our gratitude also goes out to the team at Trevi, the investigators involved in our studies, and every subject who has taken part in our clinical trials. Thank you.

Operator

operator
#29

That brings us to the end of this call. We appreciate your participation in today's presentation. You're welcome to disconnect at this time.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Trevi Therapeutics, Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

This call discussed

For developers and AI pipelines

Programmatic access to Trevi Therapeutics, Inc. earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Trevi Therapeutics, Inc. or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.